Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Drug Discov Devel. 2001 Nov;4(6):792-9.Links

The selection of a commercial route for the D1 antagonist Sch-39166.

Hou D, Schumacher D.

Rhodia ChiRex Inc, 383 Phoenixville Pike, Malvem, PA 19355, USA. donald.hou@rhodiachirex.com

D1 Antagonists have been reported to be potentially useful in a number of therapeutic areas. Sch-39166 is an example of such a selective D1 antagonist. Three different routes based on (1S,2S)-1-phenyl-1,3-propanediol (19), (+)-L-homophenylalanine (27) or trans-(+)-(1R,2R)-2-hydroxy-1-(methylamino)-1,2,3,4-tetrahydronaphthalene (37) were developed for the commercial preparation of Sch-39166. After analyzing each route for the best combination of cost, yield, throughput and efficiency, the synthesis of Sch-39166 starting from 37, which involves the opening of an aziridinium, was selected for optimization into the commercial route.

PMID: 11899619 [PubMed - indexed for MEDLINE]